Fundraising FoxCatalio Capital Management — 2022 Investments
7 investments dated 2022 · listed companies and verified rows first · show all
Octant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesEmeryville, US
Sri Kosuri(Founder)inRamsey Homsany(Founder)inRobert Andrade(Executive Officer, Director, Promoter)Maurice J. Costantini(Executive Officer, Director, Promoter)
Co-investorsAndreessen Horowitz+ND Capital8VCCarbon SiliconCatalio Capital Management, LPExplorer Investments+10 more
Pheast Therapeutics develops immunotherapies targeting cancer, building on foundational research from Stanford's stem cell research institute.
BiotechHealthtechMedical DevicesRedwood City, US
Irv Weissman(Cofounder, Scientific Advisor, Board Director)Ravi Majeti(Cofounder, Scientific Advisor, Board Observer)Amira Barkal(Principal Founder, Scientific Advisor, Board Director)inRoy Maute(Cofounder & Chief Executive Officer)in
BoardJacob Vogelstein(Director)Steven Gillis(Director)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPAlexandria
The company develops diagnostics and biological sample collection devices, including a rapid sickle-cell test, supporting infectious disease detection and genomic, metabolomic, and microbiome research.
BiotechHealthtechMedical DevicesCambridge, US
Rahul Dhanda(Executive Officer, Director)inJames Collins(Director)David Walt(Director)in
BoardIssi Rozen(Director)in
Co-investorsCatalio Capital Management, LPGaingelsIllumina VenturesGood VenturesGV (Google Ventures)Northpond Ventures+1 more
__Twitter.png)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Haystack OncologyPerceive BiotherapeuticsXilis, Inc.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.